Tag: prostate

teleflex featured

Teleflex announces collaboration with FundamentalVR to improve training through virtual reality...

Teleflex has announced a new agreement with FundamentalVR, a company providing virtual reality (VR) integration for medical simulation. The agreement will provide Teleflex with...
pae tiago bilhim

“Promising” 10-year findings on PAE for BPH presented at ET 2022

Tiago Bilhim (Saint Louis Hospital, Lisbon, Portugal) presented during the Scientific Paper session at this year’s European Conference on Embolotherapy (22–25 June, Nice, France),...
teleflex featured

New data reinforce efficacy of the UroLift system for the treatment...

Teleflex has announced the results of several research studies that further support the safety and efficacy of the UroLift system for men living with...
urolift

Teleflex completes acquisition of UroLift creator, NeoTract

Teleflex has announced the completion of its previously announced acquisition of NeoTract. Founded in 2004, NeoTract is a privately-held medical device company that has developed...

Augmenix announces first prostate cancer patients treated with SpaceOAR hydrogel in...

Augmenix, a medical technology company that develops, manufactures, and sells proprietary absorbable hydrogels that separate and protect organs at risk during radiotherapy and interventional...

Embosphere receives US FDA de novo classification for prostatic artery embolization

Merit Medical has announced that it has received 513(f)(2) (de novo) classification from the FDA to expand indication for its Embosphere microspheres. The indication...

High radiation dose to operator with prostatic artery embolization, until imaging...

According to our results, the physician who performs prostatic artery embolization procedures, even with a ceiling suspended shield, would reach the annual radiation limit...
Joao Pisco and prostate artery emoblization

1,000-patient study indicates prostate artery embolization remains effective for years

Prostate artery embolization maintains its effectiveness for at least three years after patients undergo the therapy, according to research presented at the Society of...

Mentice releases world’s first endovascular simulation training software module for prostatic...

Mentice has announced the release of the world’s first simulation training software module for prostatic artery embolization. The software, created from real patients’ data,...